Literature DB >> 7184466

Pharmacokinetics of 8-methoxypsoralen in serum and suction blister fluid.

J Lauharanta, T Juvakoski, L Kanerva, A Lassus.   

Abstract

Micronized 8-methoxypsoralen (8-MOP), with a smaller crystal size, produced significantly higher serum level profiles than nonmicronized 8-MOP. Furthermore, the absorption of the micronized drug was more rapid, resulting in peak serum levels within 1 h in 75% of the patients. Our blister fluid studies suggest, however, that reduction of the photosensitizer concentration is slower in skin than in serum. This implies that despite markedly reduced 8-MOP serum level after 2 h the skin remains sufficiently sensitized up to that point of time.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7184466     DOI: 10.1007/bf00509034

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  12 in total

1.  Serum level profiles of 8-methoxypsoralen after oral administration.

Authors:  I Steiner; T Prey; F Gschnait; J Washüttl; F Greiter
Journal:  Arch Dermatol Res       Date:  1977-09-27       Impact factor: 3.017

2.  Phototesting and dosimetry for photochemotherapy.

Authors:  K Wolff; F Gschnait; H Hönigsmann; K Konrad; J A Parrish; T B Fitzpatrick
Journal:  Br J Dermatol       Date:  1977-01       Impact factor: 9.302

3.  Suction blister device for separation of viable epidermis from dermis.

Authors:  U Kiistala
Journal:  J Invest Dermatol       Date:  1968-02       Impact factor: 8.551

4.  8-Methoxypsoralen-gas chromatographic determination and serum kinetics.

Authors:  J Gazith; W Schalla; H Schaefer
Journal:  Arch Dermatol Res       Date:  1978-11-10       Impact factor: 3.017

5.  Biochemical composition of suction blister fluid determined by high resolution multicomponent analysis (capillary gas chromatography--mass spectrometry and two-dimensional electrophoresis).

Authors:  G Volden; A K Thorsrud; I Bjørnson; E Jellum
Journal:  J Invest Dermatol       Date:  1980-11       Impact factor: 8.551

6.  8-MOP plasma levels in PUVA problem cases with psoriasis.

Authors:  G Wagner; C Hofmann; U Busch; J Schmid; G Plewig
Journal:  Br J Dermatol       Date:  1979-09       Impact factor: 9.302

7.  Serum levels of 8-methoxypsoralen: difference between two oral methods of administration.

Authors:  L Stolk; A Kammeyer; R H Cormane; P A Van Zwieten
Journal:  Br J Dermatol       Date:  1980-10       Impact factor: 9.302

8.  Pharmacokinetics and metabolite-pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dog.

Authors:  U Busch; J Schmid; F W Koss; H Zipp; A Zimmer
Journal:  Arch Dermatol Res       Date:  1978-08-28       Impact factor: 3.017

9.  Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with meladinin tablets.

Authors:  P Thune
Journal:  Acta Derm Venereol       Date:  1978       Impact factor: 4.437

10.  Photochemotherapy of psoriasis with relevance to 8-methoxypsoralen plasma level and low intensity irradiation.

Authors:  P Thune; G Volden
Journal:  Acta Derm Venereol       Date:  1977       Impact factor: 4.437

View more
  3 in total

1.  Peak blistering point: influence on fluid levels of 5-MOP in human skin in vivo after systemic administration.

Authors:  P Humbert; P Treffel; S Makki; J Millet; P Agache
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

Review 2.  Clinical pharmacokinetics of methoxsalen and other psoralens.

Authors:  F A de Wolff; T V Thomas
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

3.  Intake of Furocoumarins and Risk of Skin Cancer in 2 Prospective US Cohort Studies.

Authors:  Weiyi Sun; Megan S Rice; Min K Park; Ock K Chun; Melissa M Melough; Hongmei Nan; Walter C Willett; Wen-Qing Li; Abrar A Qureshi; Eunyoung Cho
Journal:  J Nutr       Date:  2020-06-01       Impact factor: 4.798

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.